Company Profile

Healcisio Inc
Profile last edited on: 6/9/25      CAGE: 996Q0      UEI: C36QKLWW23Y5

Business Identifier: A healthcare technology startup focused on bringing state-of-the-art AI-based diagnostic tools to \ bedsid
Year Founded
2022
First Award
2023
Latest Award
2024
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3906 Caminito Cassis
San Diego, CA 92122
   (650) 678-1941
   team@healcisio.com
   www.healcisio.com
Location: Single
Congr. District: 50
County: San Diego

Public Profile

Described as a leader in AI and digital healthcare, Healicsio is recently funded to advance the development of the firm's critical care decision support platform and a new AI-powered software suite for abstracting and reporting quality measures. In what is one of the country's only peer reviewed, prospective implementation studies for sepsis AI, Healcisio has previously demonstrated a remarkable reduction in sepsis mortality by 17% and an improvement in SEP-1 bundle compliance by nearly 10%. Healcisio Management has also begun expanding this work to two additional health systems and deploying new generative AI tools related to quality assessment for the in-hospital care of sepsis patients. "Predictive analytics is an increasingly important part of the healthcare delivery process; however, it's only one factor in a highly complex system. Maturing how we measure quality and making it efficient is long overdue and can profoundly benefit patients and providers. We think Healcisio's holistic approach to this problem are intended to drive meaningful change for the treatment of sepsis and many other complex medical conditions,(quoting Aaron Boussina, Healcisio CEO). Currently hospitals receiving CMS funding are rquired to self-report a host of quality measures related to the care they deliver. Within US physician practices, annual cost of quality reporting has been reported as 785 hours per physician and over $15 billion. One of the most debated and time consuming measures is related to sepsis and is called SEP-1. The SEP-1 measure requires significant manual abstraction and time to complete. Using the latest advances in Large Language Models (LLMs), Healcisio has developed a number of quality measure automation tools, including an LLM-based system that ingests patient charts, via Fast Healthcare Interoperability Resources (FHIR), and outputs a completed Severe Sepsis and Septic Shock (SEP-1) abstraction. As part of the multi-site deployment of its sepsis AI model, Healcisio is partnering with quality improvement stakeholders with the hope of alleviating the clinical workload associated with manual chart reviews, thereby reallocating precious clinician time to enhance care quality initiatives at the patients' bedside. About Healcisio, Inc. Healcisio, Inc. is a healthcare technology startup based in La Jolla, CA, focused on bringing state-of-the-art AI-based diagnostic tools to the bedside.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Aaron Boussina

  Christopher Josef -- Director of Medical & Clinical Innovation

Company News

There are no news available.